Free Trial

Prime Medicine (PRME) Competitors

Prime Medicine logo
$3.72 +0.32 (+9.41%)
As of 09/5/2025 04:00 PM Eastern

PRME vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Prime Medicine vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

70.4% of Prime Medicine shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

180 Life Sciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. 180 Life Sciences' return on equity of 0.00% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Prime Medicine -4,016.83%-156.16%-64.41%

180 Life Sciences has higher earnings, but lower revenue than Prime Medicine.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Prime Medicine$2.98M167.99-$195.88M-$1.56-2.38

In the previous week, Prime Medicine had 3 more articles in the media than 180 Life Sciences. MarketBeat recorded 3 mentions for Prime Medicine and 0 mentions for 180 Life Sciences. Prime Medicine's average media sentiment score of 0.20 beat 180 Life Sciences' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
180 Life Sciences Neutral
Prime Medicine Neutral

Summary

Prime Medicine beats 180 Life Sciences on 5 of the 8 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRME vs. The Competition

MetricPrime MedicineBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$500.62M$238.22M$2.53B$9.92B
Dividend YieldN/AN/A2.53%4.51%
P/E Ratio-2.38N/A26.3226.13
Price / Sales167.99323.32110.60173.10
Price / CashN/AN/A23.1859.28
Price / Book3.182.2031.486.09
Net Income-$195.88M-$111.70M$16.40M$266.51M
7 Day PerformanceN/A-0.83%0.47%0.45%
1 Month PerformanceN/A-18.45%2.75%5.05%
1 Year PerformanceN/A115.86%31.90%26.03%

Prime Medicine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRME
Prime Medicine
N/A$3.72
+9.4%
N/AN/A$500.62M$2.98M-2.38N/ANews Coverage
Analyst Downgrade
ATNFW
180 Life Sciences
N/A$0.21
-10.6%
N/A+2,715.6%$0.00N/A0.007Positive News
Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.23
-2.5%
N/AN/A$0.00$110.87K0.0040Positive News
ALVOW
Alvotech
N/A$1.07
+2.9%
N/A-54.9%$0.00$560.10M0.004Positive News
Gap Up
High Trading Volume
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.05
+29.9%
N/A-31.1%$0.00N/A0.0015Gap Up
BFRIW
Biofrontera
N/A$0.14
-8.8%
N/AN/A$0.00$39.19M0.0070Positive News
BTMDW
biote
N/A$0.01
-15.6%
N/A-96.5%$0.00$199.07M0.00N/AGap Down
BCTXW
BriaCell Therapeutics
N/A$0.03
+1.7%
N/A-87.5%$0.00N/A0.008News Coverage
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:PRME) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners